We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nerivio

News List

FDA Approves Nerivio for Acute Treatment of Migraine in Adolescents americanpharmaceuticalreview
January 26, 2021
Theranica announced its Nerivio® therapeutic device has received the U.S. Food and Drug Administration (FDA) clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.
Nerivio Receives Expanded Indication to Cover Chronic Migraine Patients americanpharmaceuticalreview
November 02, 2020
Theranica announced its Nerivio® medical device has received U.S. Food and Drug Administration (FDA) clearance for an expanded indication encompassing acute treatment of chronic migraine in people 18 years and older.